Synergy Pharmaceuticals to Present at Piper Jaffray Healthcare Conference

Wed Nov 21, 2012 8:50am EST

* Reuters is not responsible for the content in this press release.

NEW YORK, Nov. 21, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its President and CEO, Gary S. Jacob, Ph.D, will present at the 24th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2012 at 12:30 p.m. EST at the New York Palace Hotel in New York, NY.

The webcast presentation can be accessed via the Investor Relations section of the company's website at www.synergypharma.com

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's lead proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal (GI) hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in chronic idiopathic constipation (CIC) patients. In October, 2011, Synergy initiated dosing of patients in a major Phase IIb/III clinical trial of plecanatide to treat CIC. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome (IBS-C), with the first trial in IBS-C patients planned for the second half of 2012. Synergy's second GC-C agonist SP-333 is in clinical development to treat inflammatory bowel diseases, and is presently in a Phase I trial in healthy volunteers. More information is available at http://www.synergypharma.com.

CONTACT: Danielle Spangler
         The Trout Group
         synergy@troutgroup.com
         (646) 378-2924
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.